If you had backed the bullish telehealth and hormonal health story around Hims & Hers Health a year ago, the result would have stung. Holding Hims & Hers Health over the past year would have meant a 46.6% loss, including dividends. If that decision hinged on expectations of high-teens revenue growth, mid-single digit profit margins, and a premium future P/E, what did that original case miss about regulatory risk, GLP-1 dependence, and global expansion economics?
A Narrative on Simply Wall St is one investor’s written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.
The move put Hims & Hers Health in the middle of this trade. Scan 36 healthcare AI stocks for other companies exposed to it.
The Two Stories Investors Were Weighing On Hims & Hers Health
The shares cost US$36.05 at the start of the period, and anyone looking at Hims & Hers Health then had to choose between two sharply different stories.
On the optimistic side, the bullish narrative saw a fair value of US$47.42, framed around assumptions of 18.8% revenue growth and an 8.1% profit margin, helped by telehealth expansion into hormonal health and international markets.
The bearish view pointed to a fair value of US$28, focused on mounting regulatory costs, tougher telehealth competition, and pressure on pricing power as generic rivals and price transparency grew.
What The Evidence Around Hims & Hers Health Actually Tested
The biggest development for Hims & Hers Health was the mix of higher Q3 2026 revenue of US$890.4m and a shift from a Q3 2025 profit to a Q3 2026 net loss of US$33.0m, with net margin moving from 2.6% to a loss of 3.7%. That challenged the bullish 8.1% margin assumption and lent weight to the more cautious story.
The lesson is simple. When a thesis leans on future profitability, track the direction of net margin as closely as top-line progress, especially through periods of heavy expansion and regulatory change.
What Today’s Hims & Hers Health Price Already Assumes
Hims & Hers Health now trades at US$19.73, well below where investors were debating it a year ago. The analyst consensus Narrative on Simply Wall St places its Fair Value above that quote, based on what analysts think the business could deliver.
That view leans on Hims & Hers Health turning GLP-1 weight loss, testosterone and international subscribers into long term, higher margin relationships. A buyer today would need to judge whether that shift to durable, profitable subscription depth really holds.
Read More: What Hims & Hers Health Investors Missed Before The Fall
